Form 8-K - Current report:
SEC Accession No. 0001641172-25-013249
Filing Date
2025-06-02
Accepted
2025-06-02 16:30:38
Documents
14
Period of Report
2025-06-02
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K form8-k.htm   iXBRL 8-K 84516
2 EX-3.1 ex3-1.htm EX-3.1 9043
3 EX-3.2 ex3-2.htm EX-3.2 9138
  Complete submission text file 0001641172-25-013249.txt   276365

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE erna-20250602.xsd EX-101.SCH 3015
5 XBRL LABEL FILE erna-20250602_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE erna-20250602_pre.xml EX-101.PRE 22359
16 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3819
Mailing Address 10531 4S COMMONS DRIVE SUITE 166-550 SAN DIEGO CA 92127
Business Address 1035 CAMBRIDGE STREET SUITE 18A CAMBRIDGE MA 02141 (617) 798-6700
Ernexa Therapeutics Inc. (Filer) CIK: 0000748592 (see all company filings)

EIN.: 311103425 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-11460 | Film No.: 251015478
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)